✦ LIBER ✦

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

✍ Scribed by Brada, M; Judson, I; Beale, P; Moore, S; Reidenberg, P; Statkevich, P; Dugan, M; Batra, V; Cutler, D

Book ID: 110002582
Publisher: Nature Publishing Group
Year: 1999
Tongue: English
Weight: 95 KB
Volume: 81
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6690802

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of temozolomide and escala

Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma

✍ David N. Korones; Michal Benita-Weiss; Thomas E. Coyle; Laszlo Mechtler; Peter B 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

## Abstract ## BACKGROUND Although temozolomide is active against recurrent malignant glioma, responses in many patients are modest and short‐lived. Temozolomide may prove more effective in combination with other agents. Therefore, combination oral chemotherapy for these patients is a particularly

Pilot Phase I/II Study of New Salvage Th

Pilot Phase I/II Study of New Salvage Therapy (CHASE) for Refractory or Relapsed Malignant Lymphoma

✍ Michinori Ogura; Yoshitoyo Kagami; Hirofumi Taji; Ritsuro Suzuki; Kazuhisa Miura 📂 Article 📅 2003 🏛 Carden Jennings Publishing 🌐 English ⚖ 105 KB

Phase I Dose-Escalation and Pharmacokine

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

✍ Demetri, G. D.; Lo Russo, P.; MacPherson, I. R.J.; Wang, D.; Morgan, J. A.; Brun 📂 Article 📅 2009 🏛 American Association for Cancer Research 🌐 English ⚖ 238 KB

Phase I study of the combination of irin

Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma

✍ Junji Suzumiya; Hitoshi Suzushima; Kouichi Maeda; Seiichi Okamura; Atae Utsunomi 📂 Article 📅 2004 🏛 Carden Jennings Publishing 🌐 English ⚖ 75 KB

Phase I and pharmacokinetic study of amr

Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer

✍ Isamu Okamoto; Akinobu Hamada; Yusuke Matsunaga; Ji-ichiro Sasaki; Shinji Fujii; 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 242 KB

Phase II study of arsenic trioxide and a

Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study

✍ JE Chang; PM Voorhees; JM Kolesar; HG Ahuja; FA Sanchez; GA Rodriguez; K Kim; J 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 1 views

Arsenic trioxide (As 2 O 3 ) has established clinical activity in acute promyelocytic leukaemia and has pre-clinical data suggesting activity in lymphoid malignancies. Cell death from As 2 O 3 may be the result of oxidative stress. Agents which deplete intracellular glutathione, such as ascorbic aci